Pharmacodynamic monitoring of cyclosporine A by NFAT-regulated gene expression and the relationship with infectious complications in pediatric renal transplant recipients

Pediatric Transplantation

Volumn 14, Issue 7, 2010, Pages 844-851

  Billing, Heiko ^a   Giese, Thomas ^b   Sommerer, Claudia ^b   Zeier, Martin ^b   Feneberg, Reinhard ^a   Meuer, Stefan ^b   Tönshoff, Burkhard ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

cyclosporine A; immunosuppression; pediatric renal transplantation; pharmacodynamic monitoring

Indexed keywords

CYCLOSPORIN A; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; TRANSCRIPTION FACTOR NFAT;

ACCURACY; ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; CHILD; CLINICAL ARTICLE; DRUG BLOOD LEVEL; FEMALE; GENE EXPRESSION REGULATION; GENE TARGETING; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MALE; PHARYNGITIS; POPULATION; PRESCHOOL CHILD; PROSPECTIVE STUDY; PYELONEPHRITIS; REAL TIME POLYMERASE CHAIN REACTION; RECURRENT INFECTION; RELIABILITY; RESPIRATORY TRACT INFECTION; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; T LYMPHOCYTE; VIRAL GASTROENTERITIS;

ADOLESCENT; ADULT; AREA UNDER CURVE; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFECTION; KIDNEY TRANSPLANTATION; LYMPHOCYTES; MALE; NFATC TRANSCRIPTION FACTORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 78349293045     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2010.01354.x     Document Type: Article

References (23)

1. Halloran PF,. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004: 351: 2715.
2. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D,. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000: 342: 605.
3. Andoh TF, Bennett WM,. Chronic cyclosporine nephrotoxicity. Curr Opin Nephrol Hypertens 1998: 7: 265.
4. Tönshoff B, Melk A,. Immunosuppression in pediatric kidney transplantation. In:, Geary DF, Schaefer F, eds. Comprehensive Pediatric Nephrology. Philadelphia, PA: Mosby, 2008: p. 905.
5. Nashan B, Bock A, Bosmans JL, et al. Use of Neoral C monitoring: A European consensus. Transpl Int 2005: 18: 768.
6. Schiff J, Cole E, Cantarovich M,. Therapeutic monitoring of calcineurin inhibitors for the nephrologist. Clin J Am Soc Nephrol 2007: 2: 374.
7. Hartel C, Fricke L, Schumacher N, et al. Delayed cytokine mRNA expression kinetics after T-lymphocyte costimulation: A quantitative measure of the efficacy of cyclosporin A-based immunosuppression. Clin Chem 2002: 48: 2225.
8. Giese T, Zeier M, Schemmer P, et al. Monitoring of NFAT-regulated gene expression in the peripheral blood of allograft recipients: A novel perspective toward individually optimized drug doses of cyclosporine A. Transplantation 2004: 77: 339.
9. Sommerer C, Giese T, Meuer S, Zeier M,. Pharmacodynamic monitoring of calcineurin inhibitor therapy: Is there a clinical benefit? Nephrol Dial Transplant 2009: 24: 21.
10. Halloran PF, Helms LM, Kung L, Noujaim J,. The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplantation 1999: 68: 1356.
11. Stein CM, Murray JJ, Wood AJ,. Inhibition of stimulated interleukin-2 production in whole blood: A practical measure of cyclosporine effect. Clin Chem 1999: 45: 1477.
12. Sindhi R, LaVia MF, Paulling E, et al. Stimulated response of peripheral lymphocytes may distinguish cyclosporine effect in renal transplant recipients receiving a cyclosporine+rapamycin regimen. Transplantation 2000: 69: 432.
13. Sommerer C, Konstandin M, Dengler T, et al. Pharmacodynamic monitoring of cyclosporine a in renal allograft recipients shows a quantitative relationship between immunosuppression and the occurrence of recurrent infections and malignancies. Transplantation 2006: 82: 1280.
14. Konstandin MH, Sommerer C, Doesch A, et al. Pharmacodynamic cyclosporine A-monitoring: Relation of gene expression in lymphocytes to cyclosporine blood levels in cardiac allograft recipients. Transpl Int 2007: 20: 1036.
15. Sommerer C, Hartschuh W, Enk A, Meuer S, Zeier M, Giese T,. Pharmacodynamic immune monitoring of NFAT-regulated genes predicts skin cancer in elderly long-term renal transplant recipients. Clin Transplant 2008: 22: 549.
16. Sommerer C, Giese T, Schmidt J, Meuer S, Zeier M,. Ciclosporin A tapering monitored by NFAT-regulated gene expression: A new concept of individual immunosuppression. Transplantation 2008: 85: 15.
17. Ptachcinski RJ, Venkataramanan R, Burckart GJ,. Clinical pharmacokinetics of cyclosporin. Clin Pharmacokinet 1986: 11: 107.
18. Cooney GF, Habucky K, Hoppu K,. Cyclosporin pharmacokinetics in paediatric transplant recipients. Clin Pharmacokinet 1997: 32: 481.
19. Weber LT, Armstrong VW, Shipkova M, et al. Cyclosporin A absorption profiles in pediatric renal transplant recipients predict the risk of acute rejection. Ther Drug Monit 2004: 26: 415.
20. Weber LT, Hoecker B, Armstrong VW, Oellerich M, Tönshoff B,. Validation of an abbreviated pharmacokinetic profile for the estimation of mycophenolic acid exposure in pediatric renal transplant recipients. Ther Drug Monit 2006: 28: 623.
21. Schwartz GJ, Brion LP, Spitzer A,. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am 1987: 34: 571.
22. Hanley JA, McNeil BJ,. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983: 148: 839.
23. Marzolini C, Paus E, Buclin T, Kim RB,. Polymorphisms in human MDR1 (P-glycoprotein): Recent advances and clinical relevance. Clin Pharmacol Ther 2004: 75: 13.